- At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52)
- ELEVIDYS gene th… [+20116 chars]
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients - Sarepta Therapeutics
A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative…
Source:Sarepta.com
Published:
Related News
Column | I let ChatGPT analyze a decade of my Apple Watch data. Then I called my doctor. - The Washington Post
I gave the new ChatGPT Health access to 29 million steps and 6 million heartbeat measurements. It drew questionable conclusions that changed each time I asked.
The Washington Post•Geoffrey A. Fowler
Opinion | An old problem could stop the U.S. from leading on quantum computers - The Washington Post
The winner of the race for the futuristic tech could be determined by supply-chain bottlenecks.
The Washington Post•Chris Miller, Josh Zoffer
Quantum Computing Stocks: IonQ To Acquire SkyWater In $1.8 Billion Deal - Investor's Business Daily
IonQ, the most aggressive acquirer among quantum computing stocks, agreed to buy SkyWater for $1.8 billion in a cash and stock deal.
Investor's Business Daily